In fact, inhibition of SPT by compound-2 (a novel SPT inhibitor [181,193]) not only caused the expected reduction in ceramide and SM, but also exhibited anti-tumor activity in a mouse model of AML. The gene discussed is AGXT; the disease is acute myeloid leukemia.